补中助长方联合赖氨肌醇维B_(12)治疗学龄前特发性矮小症疗效观察  

Effect Observation of Buzhong Zhuzhang Prescription Combined with Lysine Inosite and Vitamin B_(12)for Idiopathic Short Stature in Preschool Children

作　　者：孙凤平 崔伟锋[2] 韩雪 SUN Fengping;CUI Weifeng;HAN Xue

机构地区：[1]河南省儿童医院(郑州儿童医院),河南郑州州450053 [2]河南省中医药研究院,河南郑州450004

出　　处：《新中医》2022年第23期130-133,共4页New Chinese Medicine

基　　金：河南省科技攻关项目(182102310395);河南省医学科技攻关项目(LHGJ20190916)。

摘　　要：目的:观察补中助长方联合赖氨肌醇维B_(12)促进学龄前特发性矮小症(ISS)患儿生长的疗效。方法:采用回归性队列研究方法,收集142例符合选入标准的学龄前ISS患儿,按接受治疗方案的不同分为观察组及对照组。对照组给予赖氨肌醇维B_(12)口服液,观察组给予口服补中助长方联合赖氨肌醇维B_(12)口服液。混杂因素采用倾向评分匹配法处理,观察并统计分析匹配后2组患儿治疗6个月、12个月后身高(H)、身高增长速度(GV)、身高落后标准差(HtSDS)、体质量指数(BMI)、年龄/骨龄比值(CA/BA)以及生长激素激发试验所得血清生长激素峰值(GHP)、血清胰岛素样生长因子1(IGF-1)、胰岛素样生长因子结合蛋白3 (IGFBP3)水平的变化,并进行安全性分析。结果:匹配前,2组H、CA/BA、HtSDS、GHP、IGF-1比较,差异有统计学意义(P<0.05)。治疗12个月后,观察组H指标值高于对照组(P<0.05)。治疗6个月、12个月,观察组GV、HtSDS指标值高于同一时间段对照组(P<0.05)。治疗6个月、治疗12个月,2组GHP比较,差异均无统计学意义(P>0.05)。治疗6个月后,观察组IGF-1水平高于同一时间段对照组(P<0.05);治疗12个月后,观察组IGF-1、IGFBP3水平均高于同一时间段对照组,差异有统计学意义(P<0.05)。治疗过程中,2组患儿均无特殊不适。结论:补中助长方联合赖氨肌醇维B_(12)能有效促进学龄前ISS患儿生长,临床使用安全。Objective:To observe the curative effect of Buzhong Zhuzhang Prescription combined with lysine inosite vitamin B_(12)on growth in preschool children with idiopathic short stature(ISS).Methods:A total of 142 cases of preschool children with ISS who met the selection criteria were collected by method of regression cohort study,and divided into the observation group and the control group according to different treatments.The control group was treated with lysine inosite vitamin B_(12)oral solution,and the observation group was additionally given the oral administration of Buzhong Zhuzhang Prescription combined with lysine inosite vitamin B_(12)oral solution.The confounding factors were treated by propensity score matching method.After matching,the changes in height(H),growth velocity(GV),height standard deviation scores(HtSDS),body mass index(BMI) and chronological age/bone age(CA/BA) ratio,as well as levels of serum growth hormone peak(GHP),serum insulin-like growth factor-1(IGF-1) and insulin-like-factor-bindingprotein 3(IGFBP-3) after 6 and 12 months of treatment were observed,counted and analyzed between the two groups.The safety was analyzed.Results:Before matching,there was significant difference being found in the comparison of H,CA/BA,HtSDS,GHP and IGF-1 between the two groups(P 0.05).After6 months of treatment,IGF-1 level in the observation group was higher than that in the control group at the same time period(P<0.05).After 12 months of treatment,levels of IGF-1 and IGFBP3 in the observation group were higher than those in the control group at the same time period,the difference being significant(P<0.05).During the treatment,both groups of children had no special discomfort.Conclusion:Buzhong Zhuzhang Prescription combined with lysine inosite vitamin B_(12)can effectively promote growth in preschool children with ISS,which is safe for clinical use.

关 键 词：特发性矮小症 补中助长方 赖氨肌醇维B_(12) 安全性 

分 类 号：R272[医药卫生—中医儿科学]